MP Pharmaceuticals Subsidy Announces New Investment Incentives for Pharma Manufacturers

NAGPUR, India - July 17, 2026 - PRLog -- The Government of Madhya Pradesh has introduced the MP Pharmaceuticals subsidy under its Pharmaceuticals Policy 2025 to encourage investment in pharmaceutical manufacturing, biotechnology, and life sciences. The policy provides a range of fiscal incentives aimed at strengthening the state's pharmaceutical ecosystem while attracting both domestic and international investors.

The policy supports investment across several segments, including Active Pharmaceutical Ingredients (APIs), Bulk Drugs, Biologics, Biosimilars, Biopharmaceuticals, Generic Medicines, Nutraceuticals, Bioinformatics, Bio Services, and Life Sciences.

According to the policy provisions, eligible industrial units may receive financial assistance for infrastructure development, environmental sustainability initiatives, intellectual property protection, testing facilities, and employment generation.

Major Incentives under the MP Pharmaceuticals Subsidy

The policy includes several investment support measures, such as:

• Infrastructure development assistance for utilities including roads, power, water supply, gas pipelines, drainage, and sewage systems.
• Capital assistance for pollution control equipment, Effluent Treatment Plants (ETP), Sewage Treatment Plants (STP), and Zero Liquid Discharge systems.
• Reimbursement of eligible expenses incurred for patents, trademarks, copyrights, geographical indications (GI), and approved organic certifications.
• Financial incentives for pharmaceutical companies employing persons with disabilities through reimbursement of eligible training costs, employee welfare contributions, and medical insurance.
• Capital assistance for establishing approved pharmaceutical testing facilities.

A key feature of the policy is the Basic Investment Promotion Assistance (BIPA), where incentive levels are linked to eligible fixed capital investment. Additional incentive multipliers are available for export-oriented units and projects with qualifying Foreign Direct Investment (FDI).

Growing Opportunities for the Pharmaceutical Sector

India's pharmaceutical industry continues to expand, creating increasing demand for advanced manufacturing facilities and research-driven investments. The MP Pharmaceuticals Policy 2025 seeks to improve industrial competitiveness by supporting sustainable manufacturing practices, innovation, exports, and value-added pharmaceutical production.

Industry Advisory

Government incentive schemes involve technical eligibility criteria, documentation requirements, and compliance procedures. Businesses planning pharmaceutical manufacturing projects often undertake professional feasibility assessments before applying for incentives.

Additional information on the MP Pharmaceuticals subsidy (https://finraja.com/mp-pharmaceuticals-policy-2025/), including eligibility criteria and fiscal incentives, is available in the published policy analysis.

"The MP Pharmaceuticals Policy 2025 reflects Madhya Pradesh's focus on strengthening pharmaceutical manufacturing by supporting investment, innovation, exports, and sustainable industrial development. Businesses planning new pharmaceutical projects should carefully assess the policy provisions and eligibility criteria to understand the incentives available for their investments.", said by a spokesperson from Finraja Consultancy.

About Finraja Consultancy

Finraja Consultancy Private Limited is a financial and business advisory firm specializing in government subsidies, industrial incentive policies, project finance, and MSME consultancy. The firm publishes research-based insights on policies such as the MP Pharmaceuticals Policy 2025, helping businesses understand eligibility criteria, fiscal incentives, and investment opportunities across Central and State Government schemes.

Media Contact:

Finraja Consultancy Pvt. Ltd.
Phone: +91-9373114747 / 07122461971 / 9028491504
Website: finraja.com (https://finraja.com/contact/)